A Risk-Benefit Assessment of Interleukin-2 as an Adjunct to Antiviral Therapy in HIV Infection

ISSN： 0114-5916

Source： Drug Safety, Vol.22, Iss.1, 2000-01, pp. : 19-31

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Risk-Benefit Assessment of HIV Protease Inhibitors

By Moyle G.J. Gazzard B.G.

Drug Safety, Vol. 20, Iss. 4, 1999-04 ,pp. : 299-321

Adis International

Access to resources Recommend Favorite

Hormone Replacement Therapy in Postmenopausal Women With Diabetes Mellitus: A Risk-Benefit Assessment

By Andersson B.

Drugs & Aging, Vol. 17, Iss. 5, 2000-11 ,pp. : 399-410

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus

By Howlett H.C.S.

Drug Safety, Vol. 20, Iss. 6, 1999-06 ,pp. : 489-503

Adis International

Access to resources Recommend Favorite

Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection

By Wyatt Christina M Klotman Paul E

Expert Opinion on Drug Safety, Vol. 5, Iss. 2, 2006-03 ,pp. : 275-287

Informa Healthcare

Access to resources Recommend Favorite

Risk–benefit effects of tocolytic therapy

By Pryde Peter G Janeczek Susan Mittendorf Robert

Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. : 639-654

Informa Healthcare

Access to resources Recommend Favorite